Evaluation of Covid-19 Vaccines Side Effects among Staff and Students of Misurata University in Libya
Main Article Content
Abstract
After a year of COVID-19 being distributed in all countries worldwide, several COVID-19 vaccines were invented by different companies. All of these vaccines got emergency approval from WHO because of critical conditions to fight this pandemic, but still, scientists work on clinical experiments to approve the safety of these vaccines and their adverse effects. This research tried to check the safety of vaccines imported from the Libyan Health Ministry. The comparison was among Sinovak, Sinopharm, AstraZeneka, Sputnik V, and Pfizer- BioNTech vaccines. The research aimed to compare the side effects of each vaccine after 24 hours of vaccination, this information was collected from people who work or study at Misurata University. The first notice of survey results was the small number of people who took the second dose of all vaccines, even if all second doses have been provided by the health ministry with the exception of sputnik V. Most side effects were clear in sputnik V, AstraZeneka, and Pfizer- BioNTech, on the other hand, Sinopharm and Sinovac were mostly with little side effects although some people had headache and fever. This research recommends for more action forward campaign that aims to convince Libyan people to get COVID-19 vaccines.
Downloads
Download data is not yet available.
Article Details
How to Cite
Evaluation of Covid-19 Vaccines Side Effects among Staff and Students of Misurata University in Libya. (2022). Jurnal Biota, 8(2), 59-65. https://doi.org/10.19109/Biota.v8i2.11383
Section
Artikel
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
How to Cite
Evaluation of Covid-19 Vaccines Side Effects among Staff and Students of Misurata University in Libya. (2022). Jurnal Biota, 8(2), 59-65. https://doi.org/10.19109/Biota.v8i2.11383
References
Abu-Hammad, O., Alduraidi, H., Abu-Hammad, S., Alnazzawi, A., Babkair, H., Abu-Hammad, A., Dar-Odeh, N. (2021). Side effects reported by Jordanian healthcare workers who received covid-19 vaccines. Vaccines, 9(6), 1–10. https://doi.org/10.3390/vaccines9060577
Babamahmoodi, F., Saeedi, M., & Navaei, R. A. (2021). Side effects and immunogenicity following administration of the Sputnik V COVID ‑ 19 vaccine in health care workers in Iran. Scientific Reports, 1–8. https://doi.org/10.1038/s41598-021-00963-7
Djanas, D., Yusirwan, Martini, R. D., Rahmadian, Putra, H., Zanir, A., … Nindrea, R. D. (2021). Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. Data in Brief, 36, 107098. https://doi.org/10.1016/j.dib.2021.107098
Gasibat, Q., Raba, A. A., & Abobaker, A. (2020). COVID-19 in Libya, fewer cases so far. Any speculations? Disaster Medicine and Public Health Preparedness, 1–2. https://doi.org/10.1017/dmp.2020.177
Gulati, A., Pomeranz, C., Qamar, Z., Thomas, S., Frisch, D., George, G., Summer, R., DeSimone, J., & Sundaram, B. (2020). A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic. The American journal of the medical sciences, 360(1), 5–34. https://doi.org/10.1016/j.amjms.2020.05.006
Khan, T., Agnihotri, K., Tripathi, A., Mukherjee, S., Agnihotri, N., & Gupta, G. (2020). Covid-19: A worldwide, zoonotic, pandemic outbreak. Alternative Therapies in Health and Medicine, 26, 56–64.
Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., & Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial agents, 55(3), 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nature medicine, 27(2), 225–228. https://doi.org/10.1038/s41591-020-1124-9
Libya, Data. (n.d.). 2009, from https://data.worldbank.org/country/libya. Retrieved September 16
Lin, Y., Hu, Z., Zhao, Q., Alias, H., Danaee, M., & Wong, L. P. (2020). Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS neglected tropical diseases, 14(12), e0008961. https://doi.org/10.1371/journal.pntd.0008961
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224-3
Meo, S. A., Alhowikan, A. M., Al-Khlaiwi, T., Meo, I. M., Halepoto, D. M., Iqbal, M., Usmani, A. M., Hajjar, W., & Ahmed, N. (2020). Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. European review for medical and pharmacological sciences, 24(4), 2012–2019. https://doi.org/10.26355/eurrev_202002_20379
Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European review for medical and pharmacological sciences, 25(3), 1663–1669. https://doi.org/10.26355/eurrev_202102_24877
Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Gong, M. N., … IVY Network (2021). Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR. Morbidity and mortality weekly report, 70(38), 1337–1343. https://doi.org/10.15585/mmwr.mm7038e1
Soiza, R. L., Scicluna, C., & Thomson, E. C. (2021). Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing, 50(2), 279–283. https://doi.org/10.1093/ageing/afaa274
Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … IVY Network (2021). Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR. Morbidity and mortality weekly report, 70(34), 1156–1162. https://doi.org/10.15585/mmwr.mm7034e2
Xing, K., Tu, X. Y., Liu, M., Liang, Z. W., Chen, J. N., Li, J. J., Jiang, L. G., Xing, F. Q., & Jiang, Y. (2021). Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 23(3), 221–228. https://doi.org/10.7499/j.issn.1008-8830.2101133
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4
Babamahmoodi, F., Saeedi, M., & Navaei, R. A. (2021). Side effects and immunogenicity following administration of the Sputnik V COVID ‑ 19 vaccine in health care workers in Iran. Scientific Reports, 1–8. https://doi.org/10.1038/s41598-021-00963-7
Djanas, D., Yusirwan, Martini, R. D., Rahmadian, Putra, H., Zanir, A., … Nindrea, R. D. (2021). Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. Data in Brief, 36, 107098. https://doi.org/10.1016/j.dib.2021.107098
Gasibat, Q., Raba, A. A., & Abobaker, A. (2020). COVID-19 in Libya, fewer cases so far. Any speculations? Disaster Medicine and Public Health Preparedness, 1–2. https://doi.org/10.1017/dmp.2020.177
Gulati, A., Pomeranz, C., Qamar, Z., Thomas, S., Frisch, D., George, G., Summer, R., DeSimone, J., & Sundaram, B. (2020). A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic. The American journal of the medical sciences, 360(1), 5–34. https://doi.org/10.1016/j.amjms.2020.05.006
Khan, T., Agnihotri, K., Tripathi, A., Mukherjee, S., Agnihotri, N., & Gupta, G. (2020). Covid-19: A worldwide, zoonotic, pandemic outbreak. Alternative Therapies in Health and Medicine, 26, 56–64.
Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., & Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial agents, 55(3), 105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nature medicine, 27(2), 225–228. https://doi.org/10.1038/s41591-020-1124-9
Libya, Data. (n.d.). 2009, from https://data.worldbank.org/country/libya. Retrieved September 16
Lin, Y., Hu, Z., Zhao, Q., Alias, H., Danaee, M., & Wong, L. P. (2020). Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS neglected tropical diseases, 14(12), e0008961. https://doi.org/10.1371/journal.pntd.0008961
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224-3
Meo, S. A., Alhowikan, A. M., Al-Khlaiwi, T., Meo, I. M., Halepoto, D. M., Iqbal, M., Usmani, A. M., Hajjar, W., & Ahmed, N. (2020). Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. European review for medical and pharmacological sciences, 24(4), 2012–2019. https://doi.org/10.26355/eurrev_202002_20379
Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European review for medical and pharmacological sciences, 25(3), 1663–1669. https://doi.org/10.26355/eurrev_202102_24877
Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Gong, M. N., … IVY Network (2021). Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR. Morbidity and mortality weekly report, 70(38), 1337–1343. https://doi.org/10.15585/mmwr.mm7038e1
Soiza, R. L., Scicluna, C., & Thomson, E. C. (2021). Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing, 50(2), 279–283. https://doi.org/10.1093/ageing/afaa274
Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … IVY Network (2021). Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR. Morbidity and mortality weekly report, 70(34), 1156–1162. https://doi.org/10.15585/mmwr.mm7034e2
Xing, K., Tu, X. Y., Liu, M., Liang, Z. W., Chen, J. N., Li, J. J., Jiang, L. G., Xing, F. Q., & Jiang, Y. (2021). Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 23(3), 221–228. https://doi.org/10.7499/j.issn.1008-8830.2101133
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4